These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14747583)

  • 21. PrP P102L and Nearby Lysine Mutations Promote Spontaneous
    Kraus A; Raymond GJ; Race B; Campbell KJ; Hughson AG; Anson KJ; Raymond LD; Caughey B
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivation of transmissible spongiform encephalopathy agents in food products by ultra high pressure-temperature treatment.
    Cardone F; Brown P; Meyer R; Pocchiari M
    Biochim Biophys Acta; 2006 Mar; 1764(3):558-62. PubMed ID: 16542885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
    Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
    Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frameshifted prion proteins as pathological agents: quantitative considerations.
    Wills PR
    J Theor Biol; 2013 May; 325():52-61. PubMed ID: 23454079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies.
    Beekes M; McBride PA
    FEBS J; 2007 Feb; 274(3):588-605. PubMed ID: 17288548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo model for the evaluation of molecules active towards transmissible spongiform encephalopathies.
    Ponti W; Sala M; Pollera C; Braida D; Poli G; Bareggi S
    Vet Res Commun; 2004 Aug; 28 Suppl 1():307-10. PubMed ID: 15372984
    [No Abstract]   [Full Text] [Related]  

  • 27. Transmissible spongiform encephalopathies: vaccine issues.
    Cashman NR
    Dev Biol (Basel); 2001; 106():455-9; discussion 460-1, 465-75. PubMed ID: 11761262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prion protein interconversions.
    Caughey B
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):197-200; discussion 200-2. PubMed ID: 11260800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prions and their characteristics in light of recent tests].
    Szostek S; Zgórniak-Nowosielska I
    Przegl Lek; 1999; 56(4):321-3. PubMed ID: 10494173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins.
    Gregori L; Gurgel PV; Lathrop JT; Edwardson P; Lambert BC; Carbonell RG; Burton SJ; Hammond DJ; Rohwer RG
    Lancet; 2006 Dec; 368(9554):2226-30. PubMed ID: 17189034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elimination of transmissible spongiform encephalopathy infectivity and decontamination of surgical instruments by using radio-frequency gas-plasma treatment.
    Baxter HC; Campbell GA; Whittaker AG; Jones AC; Aitken A; Simpson AH; Casey M; Bountiff L; Gibbard L; Baxter RL
    J Gen Virol; 2005 Aug; 86(Pt 8):2393-2399. PubMed ID: 16033987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance of transmissible spongiform encephalopathy agents to decontamination.
    Taylor DM
    Contrib Microbiol; 2001; 7():58-67. PubMed ID: 11923936
    [No Abstract]   [Full Text] [Related]  

  • 33. Transmissible spongiform encephalopathies: in-vitro evaluation of the therapeutic potentiality of new molecules.
    Carcassola G; Giannino ML; Riva F; Ponti W
    Vet Res Commun; 2003 Sep; 27 Suppl 1():331-3. PubMed ID: 14535423
    [No Abstract]   [Full Text] [Related]  

  • 34. Prion encephalopathies of animals and humans.
    Prusiner SB
    Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy.
    Bartz JC; Bessen RA; McKenzie D; Marsh RF; Aiken JM
    J Virol; 2000 Jun; 74(12):5542-7. PubMed ID: 10823860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probing the dynamics of prion diseases with amphotericin B.
    Adjou KT; Deslys JP; Demaimay R; Dormont D
    Trends Microbiol; 1997 Jan; 5(1):27-31. PubMed ID: 9025232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical factors influencing prion inactivation by sodium hydroxide.
    Bauman PA; Lawrence LA; Biesert L; Dichtelmüller H; Fabbrizzi F; Gajardo R; Gröner A; Jorquera JI; Kempf C; Kreil TR; von Hoegen I; Pifat DY; Petteway SR; Cai K
    Vox Sang; 2006 Jul; 91(1):34-40. PubMed ID: 16756599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human transmissible spongiform encephalopathies: historic view.
    Asher DM; Gregori L
    Handb Clin Neurol; 2018; 153():1-17. PubMed ID: 29887130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Unconventional transmissible agents or prions].
    Dormont D
    Presse Med; 1997 Mar; 26(9):425-30. PubMed ID: 9137406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of prion-induced neurodegeneration.
    Saá P; Harris DA; Cervenakova L
    Expert Rev Mol Med; 2016 Apr; 18():e5. PubMed ID: 27055367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.